Comparison · NCT00006164-sae
Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Peginterferon Alfa-2a 90 mcg/Week vs Standard of Care Followup: serious adverse events. Trial comparisons, record NCT00006164-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00006164-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.338 | 0.299 | 0.38 | wilson | |
| Risk in group 2 | 0.291 | 0.254 | 0.331 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0477 | -0.00847 | 0.104 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.16 | 0.973 | 1.39 | log | |
| Odds ratio, group 1 over group 2 | 1.25 | 0.961 | 1.62 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Peginterferon Alfa-2a 90 mcg/Week than on Standard of Care Followup | 21 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: standard of care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Peginterferon Alfa-2a 90 mcg/Week | Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months | 175 | 517 | EG000 |
| Group 2 | Standard of Care Followup | Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment | 155 | 533 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Within 1400 days (3.83 years) after randomization
Source ClinicalTrials.gov
Trial
- Title
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
- NCT number
- NCT00006164
- Phases
- PHASE3
- Conditions
- Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
- Interventions
- Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Results first posted
- 2009-09-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00006164?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00006164-sae